Yubo Wang

List of Publications by Year
in descending order

26 papers	1,040 citations	516710 16 h-index	552781 26 g-index
28 all docs	28 docs citations	28 times ranked	1826 citing authors

#	Article	IF	Citations
1	Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib. Frontiers in Oncology, 2022, 12, 875313.	2.8	4
2	Biological Significance of 18F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients. International Journal of General Medicine, 2021, Volume 14, 347-356.	1.8	7
3	VPS34 suppression reverses osimertinib resistance via simultaneously inhibiting glycolysis and autophagy. Carcinogenesis, 2021, 42, 880-890.	2.8	9
4	Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phase. Cost Effectiveness and Resource Allocation, 2021, 19, 44.	1.5	3
5	Hexokinases <scp>II</scp>â€mediated glycolysis governs susceptibility to crizotinib in <scp>ALK</scp>â€positive nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 3184-3193.	1.9	10
6	Metformin attenuates TGF-Î²1-induced pulmonary fibrosis through inhibition of transglutaminase 2 and subsequent TGF-Î² pathways. 3 Biotech, 2020, 10, 287.	2.2	9
7	The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. Lung Cancer, 2020, 146, 165-173.	2.0	32
8	Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy. Journal of Thoracic Oncology, 2020, 15, 1369-1375.	1.1	68
9	Aspirin sensitizes osimertinibâ€resistant NSCLC cells inÂvitro and inÂvivo via Bimâ€dependent apoptosis induction. Molecular Oncology, 2020, 14, 1152-1169.	4.6	20
10	Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1. Cell Death and Disease, 2020, 11, 111.	6.3	18
11	Characterization of an Asymptomatic Cohort of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Individuals Outside of Wuhan, China. Clinical Infectious Diseases, 2020, 71, 2132-2138.	5.8	96
12	Metforminâ€sensitized NSCLC cells to osimertinib via AMPKâ€dependent autophagy inhibition. Clinical Respiratory Journal, 2019, 13, 781-790.	1.6	17
13	Serial ultraâ€deep sequencing of circulating tumor DNA reveals the clonal evolution in nonâ€small cell lung cancer patients treated with antiâ€PD1 immunotherapy. Cancer Medicine, 2019, 8, 7669-7678.	2.8	27
14	Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer. Oncology Letters, 2019, 18, 3159-3169.	1.8	11
15	Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. Clinical Cancer Research, 2019, 25, 6967-6975.	7.0	52
16	Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer. Cancer Letters, 2019, 452, 191-202.	7.2	48
17	Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.. Journal of Clinical Oncology, 2019, 37, 9035-9035.	1.6	1
18	Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib. Lung Cancer, 2018, 118, 105-110.	2.0	53

#	Article	IF	Citations
19	The Utility of ¹⁸F-FDG PET/CT for Monitoring Response and Predicting Prognosis after Glucocorticoids Therapy for Sarcoidosis. BioMed Research International, 2018, 2018, 1-6.	1.9	11
20	Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction. Oncotarget, 2017, 8, 93825-93838.	1.8	22
21	A transcriptional miRNA-gene network associated with lung adenocarcinoma metastasis based on the TCGA database. Oncology Reports, 2016, 35, 2257-2269.	2.6	12
22	Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway. Oncotarget, 2016, 7, 34442-34452.	1.8	41
23	Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-Î² signaling pathway. Oncotarget, 2015, 6, 43605-43619.	1.8	86
24	Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. Cancer Letters, 2015, 369, 97-102.	7.2	82
25	Metformin Sensitizes EGFR-TKIâ€“Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal. Clinical Cancer Research, 2014, 20, 2714-2726.	7.0	212
26	Metformin Inhibits the IL-6-Induced Epithelial-Mesenchymal Transition and Lung Adenocarcinoma Growth and Metastasis. PLoS ONE, 2014, 9, e95884.	2.5	89